Although the PI3K–AKT–mTOR pathway is frequently activated in SCCHN,7,8 the efficacy data from the clinical trial as well as from PDX models showed the tumour to be highly resistant to buparlisib monotherapy. This evidence concerns the gene AKT1 and neoplasm.